Hyper-activated LRRK2 is linked to Parkinson's disease susceptibility and progression.
Introduction
Leucine-rich repeat kinase 2 (LRRK2) small molecule kinase inhibitors and anti-sense oligonucleotides have demonstrated neuroprotective efficacy in some models of Parkinson's disease (PD) and represent a promising novel class of disease modifying therapeutics for neurodegeneration. 1, 2, 3 Efforts to develop potent and selective therapies that mitigate LRRK2hyperactivation associated with pathogenic LRRK2 mutations have recently intensified in industry. 4, 5 Reliable measures of LRRK2 expression and enzymatic inhibition may assist in the identification of the most efficacious LRRK2-targeting therapies at optimized doses, particularly in early clinical trials. As some LRRK2-targeting molecules have recently progressed through initial safety trials, 6 non-invasive pharmacodynamic measures in biofluids may be valuable to establish on-target drug effects in the brain (i.e., LRRK2 kinase inhibition or reduction in total protein levels). With renewed emphasis on precision approaches in the clinic, comprehensive demonstrations of robust target engagement during initial safety trials (e.g., in acute ascending dose strategies) may help successfully identify the best molecules to transition to larger efficacy studies in limited populations of genetically-defined LRRK2-linked PD. 5, 7, 8 LRRK2 is a phospho-protein in all cells and tissues so-far evaluated, 9 with a cluster of phosphorylated residues controlled by several other kinases and phosphatases that can regulate LRRK2 interactions with 14-3-3 proteins. 10, 11, 12 Small molecule LRRK2 kinase inhibitors acutely reduce constitutive phospho-sites in LRRK2, most notably pS935, 10, 12 as well as the autophosphorylated residue pS1292 located in the C-terminal region of the LRRK2 leucine-rich repeat (LRR) domain. 13, 14, 15 LRRK2 robustly autophosphorylates its own Rab-like GTPase domain in vitro, 16, 17, 18 in addition to phosphorylating other GTP-bound Rab proteins (i.e., Rab10) both in vitro and in vivo. 19, 20 LRRK2 kinase inhibitors reduce levels of phospho-Rab10 in ex vivo inhibitor treatments of immune cells that express high levels of LRRK2 protein (e.g., monocytes, neutrophils, and whole-lysates of mononuclear cells), as well as in tissues (e.g., lung and kidney) procured from mice and rats. 21, 22, 23 pS1292-LRRK2 and pT73-Rab10 are direct substrates of LRRK2, although the phosphatases that affect these sites are likely different in cells and tissues potentially affecting pharmacodynamic marker kinetics. 24 Apart from protein pharmacodynamic markers, levels of di-docosahexaenoyl (22:6) bis (monoacylglycerol) phosphate (di-22:6-BMP) which are usually elevated in phospholipidosis and lysosomal storage diseases, 25, 26, 27 are decreased in urine from LRRK2-inhibitor treated non-human primates. 28 The mechanisms behind LRRK2-inhibitor induced decreases in di-22:6-BMP in urine have yet to be fully defined.
Recently we identified LRRK2 protein secreted by cells in a type of microvesicle called exosomes that are derived from multivesicular bodies. 29 Although only a small fraction of LRRK2 protein is secreted into exosomes, the ratio of phospho-LRRK2 to total LRRK2 levels appears comparable between exosome and total cell (or tissue) lysates. 13 The exosome fraction of biofluids (sometimes called liquid-biopsies) allows the assessment of cellular levels of proteins from tissues that are otherwise inaccessible for analysis, for example the brain. LRRK2 protein is widely expressed through the body, with inducible expression in some immune cell subsets with pro-inflammatory agonists, and constitutive tissue expression in some cells in the brain, lung, and kidney. 5, 28, 30, 31, 32 In some model systems, LRRK2 kinase inhibitors, usually in great excess of binding affinity concentrations, can reduce total LRRK2 protein levels comparably to effects seen with anti-sense LRRK2-targeting oligonucleotides. 33, 34 The reduction of total LRRK2 protein in cells and tissues may relate to how specific inhibitors interact in the ATP-pocket, whereas LRRK2 inhibitor-induced reductions in exosome secretion in biofluids may relate to LRRK2 subcellular localization changes in the endolysosomal compartment broadly caused by kinase inhibition. 23, 29, 35, 36 Although phospho-LRRK2 to total-LRRK2 ratios have been suggested as efficacious measures of LRRK2 inhibitors, 10 inhibitor-induced destabilization of LRRK2 protein or reductions of secreted LRRK2 protein may confound interpretation of these ratios.
Biochemical surveys of LRRK2 kinase activity in ex vivo assays of proteins purified from mouse-derived cells and tissues reveal much higher LRRK2 activity in the brain than in other tissues and cells. 37 Further, autophosphorylated LRRK2 protein (i.e., pS1292-LRRK2) appears particularly high in human CSF exosomes as compared to exosomes procured from human urine or lysates of immune cells. 13 As a novel potential clinical target for neurodegeneration, the ostensibly desired effect of LRRK2-directed therapies centers on robust inhibition of brain clinically-accessible pharmacodynamic biomarkers that measure brain LRRK2 inhibition. Such markers are therefore sought after but have not been previously described. Herein we better define the relationship between LRRK2 inhibition and different proposed pharmacodynamic markers, focusing on the clinically available biofluids blood, urine, and CSF. We employ structurally distinct, orally available, highly potent (low-to-sub nanomolar-binding), highlyselective, small molecule LRRK2 kinase inhibitors PFE-360, MLi2, and RA283. 23, 38 The use of non-human primates that have pharmacokinetic responses more similar to humans compared to rodents further allows the collection of sufficient volumes of urine and CSF for LRRK2 detection at the same time as blood collections to identify predictive markers of LRRK2 inhibition with the potential for translation to human studies.
Results
To measure pharmacodynamic responses related to LRRK2 kinase inhibition in macaques, PBMCs, plasma, urine, and CSF were procured from ten animals prior to drug administration.
Two groups of five macaques were then treated daily with either 5 mg kg -1 of PFE-360 or MLi2 (Supplemental Figure 1A 
Blood markers of LRRK2 kinase inhibition
LRRK2 is differentially expressed in immune cells in PBMCs, with some of the highest LRRK2 expression in monocytes, B-cells, and neutrophils. 31, 39, 40, 41 Compared to the baseline levels of total LRRK2 in PBMCs, PFE-360 treatment caused a large drop in LRRK2 levels (normalized to β-actin, unadjusted for immune cell subtypes), with just 22% average of total LRRK2 protein remaining (Mdn PFE-360 = 0.15, IQR= 0.07-0.27, t(4)= 9.45, p=.0007), and undetectable quantities of pS935-LRRK2 ( Figure 1 and Supplemental Figure 2A ). The LRRK2 autophosphorylation site pS1292-LRRK2, detectable in human CSF and urinary exosomes in past studies, 13, 42, 43, 44 was not reliably detected in PBMC lysates. Total Rab10 levels, also normalized to β-actin and unadjusted for immune cell subtypes, were variable in expression in PBMCs (Mdn PFE-360 = 1.07, IQR= 1.03-1.34, t(4)= 1.37, p=.24, Figure 1D ). Four of five macaques demonstrated a reduction in pT73-Rab10 levels (Mdn PFE-360 = 0.12, IQR= 0.06-0.42, Figure 1E , F). One outlying macaque had baseline levels of pT73-Rab10 that fell below our limit of detection (Supplemental Figure   2A , lane 1) and was excluded. Plasma levels of the phospholipid di-22:6-BMP were not reduced through PFE-360 treatments and varied in concentration, with an average of 8.07 ± 2.35 ng mL -1 at baseline and 7.50 ± 3.70 ng mL -1 after treatment.
In MLi2 treated macaques, total LRRK2 protein also diminished in PBMC pellets normalized to β-actin concentrations (Mdn MLi2 = 0.57, IQR= 0.40-0.88 t(4)=4.38, p= .01), but to a lesser extent than PFE-360, 47% diminished compared to 78% with PFE-360 on average ( Figure 1A and Supplemental Figure 2B ), consistent with our past experience with these drugs in rats and mice. 23 pS935-LRRK2 signal was detected in all MLi2-treated macaques at low levels compared to baseline (Mdn MLi2 = 0.11, IQR= 0.06-0.26, t(4)= 3.98, p=.02), although one macaque showed only a 50% reduction in pS935-LRRK2 that also had the lowest concentration of unbound plasma MLi2 (12.5 nM, Figure 1H ). pT73-Rab10 levels reduced by 71% on average (Mdn MLi2 = 0.39, IQR= 0.06-0.63, t(4)= 4.35, p=.01, Figure 1E ), even in the macaque with just 12.5 nM of drug in circulation. The ratio of pT73-Rab10 to total Rab10 protein offered a comparable indication to pT73-Rab10 measures alone (Mdn MLi2 = 0.16, IQR= 0.02-0.20, t(4)= 3.85, p=.02, Figure 1F , J). Overall these results suggest that pS935-LRRK2 and pT73-Rab10 levels are reliably reduced when normalized to β-actin in PBMCs after LRRK2 kinase inhibitor treatment, whereas total LRRK2 levels and total Rab10 levels were more variably affected.
Urine markers of LRRK2 kinase inhibition
Our previous work localized LRRK2 protein expression in urine to urinary exosomes. 42, 43, 44 Compared to baseline measures of LRRK2 in macaque urinary exosomes, PFE-360 or MLi2 treatment caused a profound decrease in several NHPs in total LRRK2 protein normalized to the exosome house-keeping protein TSG101 (Mdn PFE-360 = 0.04, IQR= 0-0.64, t(4)= 2.66, p=.06;
Mdn MLi2 = 0.02, IQR= 0.01-0.11, t(4)= 2.15, p=.10, Figure 2A and Supplemental Figure 3 ). A comparable decrease was noted with pS935-LRRK2 protein (Mdn PFE-360 = 0.21, IQR= 0.01-0.43, t(4)= 2.84, p=.05; Mdn MLi2 = 0, IQR= 0-0.04, t(4)= 2.15, p=.10, Figure 2B and Supplemental Figure 3 ). Owing to the reductions in total LRRK2 protein caused by kinase inhibition, the ratio of pS935-LRRK2 to total LRRK2 protein was much more variable in drug-responses, especially in NHPs where total LRRK2 protein was most dramatically reduced ( Figure 2C ). The LRRK2 autophosphorylation site pS1292 was not reliably detected in macaque urine. Total Rab10 levels, also normalized to the exosome housekeeper TSG101, was more variable than LRRK2 levels, with 3 of 5 PFE-360-treated and 4 of 5 MLi2-treated macaques showing decreases in total Rab10 (Mdn PFE-360 = 0.50, IQR= 0.41-2.31, t(4)= 0.10, p=.92; Mdn MLi2 = 0.27, IQR= 0.14-0.56, t(4)= 2.03, p=.11, Figure 1D ). Further decreases, albeit nominal compared to total LRRK2 decreases, were observed with pT73-Rab10 in most macaques (Mdn PFE-360 = 0.28, IQR= 0.15-1.54, t(4)= 2.25, p=.09; Mdn MLi2 = 0.12, IQR= 0.08-0.25, t(4)= 3.30, p=.03, Figure 1E ). The ratio of pT73-Rab10 to total Rab10 protein decreased in the macaques with the highest plasma concentrations of PFE-360 (~145 nM, 50% remaining from baseline, Mdn PFE-360 = 0.43, IQR= 0.30-0.71, t(4)= 3.46, p=.03) and MLi2 (~70 nM, 30% remaining from baseline, Mdn MLi2 = 0.60, IQR= 0.31-0.75, t(4)= 2.70, p=.05, Figure 2F , G, H). Overall, PFE-360 and MLi2 treatment consistently reduced total LRRK2 protein secretion in urinary exosomes. As with PBMC analyses, ratios of phospho-to total protein as a pharmacodynamic measure could be considered confounded due to variable changes of total protein levels.
Previous studies demonstrated that the phospholipid di-22:6-BMP, usually strongly elevated in phospholipidosis, 25, 26, 45 is reduced in the urine of LRRK2 knockout mice and non-human primates treated with the LRRK2 inhibitor GNE-7915. 28 We wondered whether the same effect could be obtained in exosome-depleted urine used for simultaneous measures of exosomal- 
Cerebrospinal fluid markers of LRRK2 kinase inhibition
Our previous work in biobanked human CSF demonstrated that LRRK2 protein and pS1292-LRRK2 protein can be readily measured in exosome fractions. 13 In exosomes isolated from human CSF, LRRK2 autophosphorylation at the serine 1292 residue is much higher (~5-fold increased on average), as opposed to urinary exosomes from the same subjects. 13 In macaque Figure 4B, D) . However, the reliability of the results could be confounded due to variable exosome depletion in individual samples. As with urine analyses, concentrations of di-22:6-BMP were not measured in the total CSF specimens (i.e., prior to exosome depletion) or in the isolated CSF exosomes due to CSF volume limitations in this study.
LRRK2 kinase inhibition lowers exosome LRRK2 in CSF
In past work in rats and mice, PFE-360 treatment partially reduced total LRRK2 levels in brain tissue at lower concentrations than MLi2, despite similar cell potencies and pharmacokinetics of the drugs. 23 To better resolve the relationship between brain LRRK2 kinase inhibition and LRRK2 secretion in urinary and CSF exosomes, we tested a third structurally distinct LRRK2 kinase inhibitor, known as RA283, in a low-dose group and a high-dose group (10 and 30 mg kg -1 , respectively) compared to a vehicle only-treated group. Macaques were treated (vehicle, lowdose, or high-dose) for a week and killed for the analysis of brain tissue collected at the same time as blood, urine, and CSF to explore the relationship of these fluid markers with inhibition of LRRK2 in brain tissue.
Similar to PFE-360 treatments, RA283 treatment reduced total exosome LRRK2 protein levels in the CSF in three of four treated macaques (Figure 4 and Supplemental Figure 5 ). Analysis of PBMCs showed a strong reduction of total LRRK2 levels in both low-dose and high-dose treated animals compared to vehicle-control animals (Figure 4 and Supplemental Figure 6 ). pS935-LRRK2 levels were nearly ablated at unbound drug plasma concentrations that ranged from ~3 nM to 17 nM ( Figure 4B ). Consistent with PFE-360 and MLi2 results, a near complete ablation of total LRRK2 protein levels was noted in urinary exosomes at higher plasma drug concentrations ( Figure 4C ). Evaluation of cortical brain tissue revealed lower total-LRRK2 protein levels (compared to vehicle treated) only in the high-dose animals ( Figure 4E ). It is worth noting that both doses led to reduced pS935-LRRK2 levels in brain tissue (~43% at lowest dose and ~87% at highest dose, Figure 4F ). Thus, these results demonstrate partial inhibition of LRRK2 kinase activity in brain tissue can lead to a near-complete ablation of total LRRK2 protein levels (and pS1292-LRRK2 protein) in CSF exosomes. These results are consistent with past studies in cell culture suggesting LRRK2-protein release in exosomes is sensitive to kinase inhibition potentially through blocking chaperone activity of 14-3-3. 29
Discussion
This study identifies effective quantitative measures for LRRK2 kinase inhibition in biofluids (urine and CSF) of non-human primates using three structurally distinct small-molecules (PFE-360, MLi2, and RA283). All three molecules have very high potency in blocking LRRK2 kinase activity in NHPs and excellent drug-properties for the study, yet differences emerged in inhibition profiles with different pharmacodynamic measures in PBMCs, urine, and CSF. While the current standard in the field may be to determine the ratio of phospho-LRRK2 protein to total LRRK2 protein to estimate LRRK2 kinase inhibition, our results here demonstrate that this measure may be critically confounded due to variable decreases in total LRRK2 that can be differentially influenced by distinct classes of small molecules. A trend emerged here, consistent with our past studies in transfected cell lines, 29 mice, and rats, 23 where exosome levels of total LRRK2 protein diminish prior to LRRK2-inhibitor induced decreases in brain tissue (graphically summarized in Figure 5A ). In practice, determining LRRK2 inhibitor target engagement in CSFderived exosomes revealed a similar profile of total LRRK2 protein reduction to that of the autophosphorylated LRRK2 protein (results summarized in Figure 5B ).
In past studies, we, and others, demonstrated elevated LRRK2-autophosphorylation and LRRK2 protein levels associated with PD susceptibility and LRRK2 pathogenic mutations. 13, 43, 46 With high endogenous LRRK2 expression in some types of innate immune cells, PBMCs have been championed as a source for pharmacodynamic biomarkers related to LRRK2 inhibition, 47 and are currently utilized in clinical trials. However, measures in PBMCs alone may poorly predict LRRK2 inhibition in the brain and other tissues, for example with drugs that are poorly brain penetrant or are rapidly eliminated. Further, PBMCs rapidly turn over and transiently respond to diverse stimuli. Ideally, we suggest that combinations of predictive markers that assess LRRK2 inhibition and pharmacodynamic responses across the body will better highlight the most efficacious drugs and dosage regimens. Past studies with drugs like azidothymidine demonstrate that measurements of drug concentration in CSF do not predict brain penetration of the drug and target engagement in the brain. 48, 49 We suggest that measuring CSF levels of LRRK2 protein in exosomes could contribute to establishing brain penetration in early phase clinical trials (e.g., acute safety studies).
In past work with different LRRK2 pharmacodynamic measures, despite robust results in analyzing tissues (i.e., brain, lung, kidney 23 ), we have been unable to reliably detect LRRK2 or Rab proteins in urine or CSF procured from rats or mice. The limited biofluids volume obtained from rats and mice compared to NHP appear not to be the reason since we would pool biofluids in excess of volumes studied here. While the reasons behind our limited success in rodents are not clear, we were able to establish robust measures in NHP urine and CSF to profile LRRK2 kinase inhibitors. Pairs of successful markers in each biofluids included pS935-LRRK2 and pT73-Rab10levels measured in PBMCs, total LRRK2 and di-22:6-BMP levels measured in urine exosomes and exosome-depleted urine, respectively, and levels of total LRRK2 and pS1292-LRRK2 measured in CSF exosomes. It is plausible that the inhibition profile of each drug would further change under different dosages or time intervals post-oral gavage, or in a chronic inhibition study such as an efficacy trial in the clinic. Nevertheless, we would predict this panel of markers would be capable of identifying drugs that poorly inhibit LRRK2 in the brain but effectively inhibit LRRK2 in the periphery, for example a drug that may cause differential changes in PBMC and urine markers but not in CSF markers. A further critical test of this hypothesis could involve a LRRK2 kinase inhibitor series that can be modified to either efficiently cross the blood brain barrier or be excluded from the brain. It will be critical to the success of new compounds to utilize these types of assays in early phase clinical trials to ensure sufficient target engagement in the brain. Many new compounds have high attrition rates due to presumed lack of target engagement at doses resolved in safety studies. 50 Implementing biomarker target engagement early may help improve drug development outcomes.
Pathogenic mutations in LRRK2 are now recognized as one of the most common genetic causes of neurodegeneration, and these mutations all appear to result in LRRK2 kinase hyper-activation. 5, 51, 52 Emerging studies also suggest a proportion of idiopathic PD that share hyper-activated LRRK2 phenotypes. 40, 43, 53, 54, 55 Several small-molecule LRRK2 kinase inhibitors and anti-sense oligonucleotides have been evaluated for efficacy and safety in various model systems, including non-human primates. 1, 3, 28, 34, 38, 47 Many if not most therapeutics that target central nervoussystem indications move to clinical trials without convincing biomarkers for target engagement.
Yet, the use of reliable biomarkers has been shown to increase the chance of success in the clinic. 56, 57 As potential LRRK2-targeting therapeutics like small molecule LRRK2 kinase inhibitors and LRRK2-targeting anti-sense oligonucleotides move forward, there is an acute need for validated pharmacodynamic and theragnostic markers to monitor the success of different classes of LRRK2 kinase inhibitors in blocking LRRK2 activity associated with disease. Notably, the protein measurement assays presented here are based on immunoblotting procedures that, while linear and quantitative in our protocols, 13 do not scale well into clinically available tests. Further assay development will be needed for broad clinical implementation.
Here, our data suggest that measures of pS935-LRRK2 and pT73-Rab10, each normalized to βactin, represent blood biomarkers of target engagement. PBMCs are easily procured in the clinic and provide a reliable resource for measuring LRRK2 inhibition in circulating cells. Several studies have shown high LRRK2 expression in specific immune cell subsets. 5, 31, 32, 39, 41, 58 Immunophenotyping blood from PD patients shows increased LRRK2 expression in monocytes and B-cells compared to healthy controls. 40, 54 Ex vivo treatment of PBMCs with LRRK2 kinase inhibitors result in a reduction of the constitutive LRRK2 phosphorylation site pS935-LRRK2 without acute toxicity. 59 While we can reproduce the reduction (e.g., with MLi2 treatment) or complete ablation (e.g., with PFE-360 treatment) of pS935-LRRK2, total LRRK2 levels are variably affected in PBMCs that may confound the interpretation of the ratio of phosphorylated to unphosphorylated peptide. We observe the same confounding issue with Rab10, presumably due to changes in protein turnover with phosphorylation as well as inducible expression in immune cell subtypes that may change with kinase inhibition over time, at least in NHPs.
Urine can be obtained non-invasively and in higher abundance than other biofluids, at least in humans. 13 Our recent proteomics studies suggest urinary exosomes harbor cytosolic proteins that demarcate organs across the body without enrichment of kidney proteins. 44 Exosomal LRRK2 is both dimerized and phosphorylated, mimicking cytosolic active isoforms. 29, 60, 61 LRRK2 kinase inhibitors reduced LRRK2 protein secretion in urinary exosomes, whereas pT73-Rab10 decreased in an exposure-dependent manner. Di-22:6-BMP, a biomarker of lysosomal dysregulation, was reduced in exosome-depleted urine with LRRK2 inhibitor treatment. These results were consistent with past observations of other structurally distinct LRRK2 kinase inhibitors in NHPs. 28 The observed decrease in di-22:6-BMP was similar to that observed in LRK2 KO mice, and shown to decrease with pS935-LRRK2 and pT73-Rab10 in lysates from brain, kidney, lung, and PBMCs. 19 A consequence of LRRK2 inhibition would be the decreased phosphorylation of its Rab GTPase substrates and thereby their accumulation in membranes. 14, 62 We propose that the shift in membrane-bound Rabs may affect the biogenesis, motility, and/or transport of BMP containing vesicles (e.g., exosomes, secretory lysosomes) outside of the cell, resulting in the observed decrease in BMP in the urine. 63 Although its source(s) remain unclear (i.e., BMPs are found in a variety of tissues and cell types, including brain), reported changes in urinary di-22:6-BMP appear to reflect a LRRK2-driven effect on lysosomal and secretory biology. 64 Consistent with our previous studies in cell lines, 29 we predict that LRRK2 inhibition manifests in biofluids first with the reduction of LRRK2 protein that is secreted in exosomes and, at higher drug doses or subsequent to a strong sustained exposure, manifests with reductions in total cellular levels of LRRK2 protein (illustrated in Figure 5A ). We propose that 14-3-3 chaperones LRRK2 protein to multivesicular bodies that export LRRK2 in exosomes, and this interaction becomes rapidly disrupted at lower doses of LRRK2 kinase inhibitors than those required for destabilizing LRRK2 protein in total. Our data here show that this relationship can be harnessed for effective LRRK2 target engagement assays in blood, urine, and CSF. Overall, we hope these results help provide a path to establish on-target effects of LRRK2-targeting investigational therapeutics in both the periphery and the CNS in clinical populations to improve the chances of a successful clinical trial. 
Materials and Methods

Compounds
Small-molecule LRRK2 kinase inhibitors PFE-360, MLi2, and RA283, were synthesized inhouse. The identity and high purity (i.e., >97.4% for each compound) of each compound was confirmed by nuclear-magnetic resonance and mass spectrometry. PFE-360 was originally discovered as part of a Pfizer chemistry program 65 , MLi2 was originally discovered as part of a Merck chemistry program 38, 66 , and RA283 was discovered as part of a Sanofi chemistry program. These compounds have structurally distinct pharmacophores 65, 66 (Supplemental Figure   1 ).
In vitro kinase assays show similar IC 50 potencies with the three structurally distinct inhibitors, with PFE-360 demonstrating 6 nM IC 50 inhibition for LRRK2 autophosphorylation, MLi2 demonstrating 4 nM inhibition, and RA283 demonstrating 5 nM of LRRK2-kinase inhibition in different LRRK2 kinase assays.
Selectivity profiling of over 300 protein kinases with each of these molecules reveals high selectivity. Off-target inhibition with IC 50 < 500 nM identifies two other kinases (MST-2, MAP3K5) for PFE-360, three other kinases for MLi2 (MAP3K14, CLK4, CLK2), and two other kinases for RA283 (MLK1, ACK1), with selectivity for LRRK2 >10-fold compared with any other kinase.
Non-human primate (NHP) treatment
For the PFE-360 and MLi2-treated groups, female cynomolgus macaques, with an average age of 10 years (Xishan, PRC) were orally administered 5 mg kg -1 PFE-360 or MLi2 daily for five days (N = 5 per group, 10 total). Under anesthesia (Zoletil/atropine (6/0.04 mg/kg, IM), blood, urine (via acute catheterization), and CSF (from cisterna magna) were collected before treatment (baseline) and two hours post final treatment for a longitudinal assessment. Indices of LRRK2 inhibition were comparisons of baseline levels to those levels after drug-treatment.
For the RA283 treated groups, male cynomolgus macaques, ~3.5 years (Tamarinier and Noveprim), were orally administered RA283 at a low dose (10 mg kg -1 ) and a high dose (30 mg kg -1 ) regimen for seven days together with a vehicle-only group (n=2 per group, 6 total). All procedures were performed in full compliance with standards for the care and use of laboratory animals, according to French and European Community (Directive 2010/63/EU) legislation, and approved by the local Animal Ethics Committee and the French Ministry for Research, under authorization H94-002-4 arrêté 2015-160 (10 December 2015). Urine, blood and CSF samples were collected 2 and 6 hours post final treatment for the low dose and high dose RA283 groups respectively. Indices of LRRK2 inhibition were comparisons of levels in the vehicle-only group to those in the low-and high-dose groups.
Drug plasma measurements
Unbound drug plasma concentrations were quantified by LC/MS analysis as previously described 23 .
Exosome isolation
Urine (~200 µL to 1 mL) and CSF samples (~200 µL to 1 mL) were stored at -80°C in cryo-vials (Corning) and quick thawed in a water bath at 42°C before processing. Fluids were centrifuged at 10,000 x g for 30 minutes and the supernatants were transferred to polycarbonate centrifuge tubes. Samples were then centrifuged at 150,000 x g for 2 hours at 4°C. Supernatants were used for di-22:6-BMP analyses (below). Pellets (enriched in exosomes) were lysed in Laemmli buffer
